Hyperbaric Oxygen Therapy Benefits: What Research Shows

Hyperbaric oxygen therapy (HBOT) has moved well beyond its origins in diving medicine. Once reserved almost exclusively for decompression sickness and carbon monoxide poisoning, this treatment now appears in wound care centers, sports medicine clinics, and longevity-focused practices nationwide. But what does the research actually show?

This article breaks down the current clinical evidence behind HBOT, separating well-established benefits from emerging applications that still need further study.

How Hyperbaric Oxygen Therapy Works

HBOT involves breathing pure oxygen inside a pressurized chamber. The pressure is typically set between 1.5 and 3.0 atmospheres absolute (ATA), which is one-and-a-half to three times the normal atmospheric pressure at sea level.

Under these conditions, your lungs take in significantly more oxygen than they would at normal air pressure. This extra oxygen dissolves directly into your blood plasma, cerebrospinal fluid, and other body fluids, reaching tissues that may not get adequate oxygen through normal circulation.

Key physiological effects include:

Increased oxygen delivery: Arterial oxygen levels can reach 1,824 mmHg at 2.4 ATA with 100% oxygen, compared to roughly 100 mmHg under normal conditions
Angiogenesis: Stimulates the growth of new blood vessels in oxygen-deprived tissues
Reduced inflammation: Decreases levels of pro-inflammatory cytokines while promoting anti-inflammatory responses
Enhanced immune function: Increases white blood cell activity and bacterial killing capacity
Stem cell mobilization: Research shows HBOT can increase circulating stem cells by up to 800% after a series of treatments (University of Pennsylvania, 2006)
Neuroplasticity via the hyperoxic-hypoxic paradox: A mechanism identified in recent research where intermittent hyperoxic exposure triggers hypoxia-like signaling pathways, improving cerebral perfusion and mitochondrial function

FDA-Cleared Conditions: The Strongest Evidence

The FDA has cleared hyperbaric chambers for 14 specific medical conditions, with growing momentum toward formal recognition of additional indications. These represent the applications with the most robust clinical evidence:

Wound Healing

HBOT's most well-established benefit is for chronic, non-healing wounds. A meta-analysis published in Scientific Reports (2021) found that the number of completely healed diabetic foot ulcers after HBOT (148 out of 321 patients) was significantly higher compared to standard treatment alone (75 out of 323 patients).

Patients receiving HBOT healed faster and remained healed at one year at higher rates than those without HBOT
Clinical practice guidelines recommend adding HBOT for Wagner Grade 3 or higher diabetic foot ulcers after surgical debridement
A 2017 review in Diabetes & Metabolism confirmed HBOT significantly reduces amputation risk in chronic diabetic foot ulcer patients

Chronic Venous Leg Ulcers: New 2026 Trial Data

A 2026 prospective randomized controlled trial published in PMC specifically evaluated HBOT for chronic venous leg ulcers and produced strong results:

At day 30, mean ulcer area reduction was 62.1% with HBOT versus 41.7% in the control group, a large and clinically meaningful effect size
The trial adds to the growing wound-care evidence base and may support expanding HBOT coverage for venous ulcers specifically
This is notable because venous leg ulcers affect an estimated 1-2% of the adult population and are notoriously resistant to standard wound care

Radiation Injury

HBOT is considered a standard treatment for delayed radiation injury, which can occur months or years after cancer radiation therapy. A 2026 clinically focused review published in CA: A Cancer Journal for Clinicians evaluated the current evidence and confirmed HBOT is effective for treating fibrosis, radiation proctitis, and radiation cystitis. The review specifically characterized HBOT as a well-tolerated intervention with durable benefits for chronic radiotherapy-related adverse effects.

A separate trial studying HBOT for radiation fibrosis in breast cancer survivors found reduced moderate to severe pain in the HBOT group (32%) compared to the control group (75%), and reduced fibrosis rates (33% vs. 51%). The authors described the results as "provocative" but noted they require further study in larger trials.

Carbon Monoxide Poisoning

This remains one of the original and best-supported uses of HBOT. The elevated pressure and oxygen concentration rapidly displace carbon monoxide from hemoglobin, potentially preventing long-term neurological damage.

Decompression Sickness

HBOT is the definitive treatment for divers who ascend too quickly, reducing nitrogen bubbles in the blood and tissues.

Emerging Research: What New Studies Show

Beyond the FDA-cleared applications, several newer areas of HBOT research show promising but still-developing evidence. The pace of clinical trials has picked up significantly in 2025 and 2026, with multiple randomized controlled trials now reporting results.

Post-Stroke Recovery

A 2026 randomized, double-blind, sham-controlled trial published in Neuropsychiatric Disease and Treatment evaluated 61 post-stroke depression patients. The HBOT group received a four-week treatment course, and researchers found:

Significant alleviation of depressive symptoms compared to the sham group
Increased serum BDNF (brain-derived neurotrophic factor) levels, a protein essential for neuron survival and growth
Elevated beta-NGF (nerve growth factor), supporting nerve repair and regeneration

The upregulation of both BDNF and beta-NGF is particularly significant because it points to a specific neurobiological mechanism — not just subjective symptom improvement, but measurable changes in neurotrophic factor levels that correlate with neural repair.

Long COVID Symptoms

The evidence for HBOT in long COVID continues to strengthen. A 2025 prospective registry published in Scientific Reports tracked 232 long COVID patients undergoing HBOT. Between 56% and 63% of long-term ill patients experienced meaningful improvements in mental and physical health scores at three months post-treatment.

This builds on earlier randomized controlled trial data (2022) showing HBOT significantly improved cognitive, psychiatric, fatigue, sleep, and pain symptoms. A long-term follow-up study (2024) confirmed improvements persisted at one year, with similar magnitude across most quality-of-life domains.

Some researchers have called HBOT the first clinically effective treatment for long COVID based on controlled trial evidence. While long COVID is not yet an FDA-approved indication for HBOT, the accumulating registry and RCT data may push toward formal recognition as larger confirmatory trials report results.

Traumatic Brain Injury

A February 2025 double-blind randomized trial found that adults with persistent brain injury symptoms experienced meaningful improvements:

HBOT group reported an average 10.6-point improvement on a standardized symptom inventory
Control group showed only a 3.6-point improvement
Improvements in anxiety, sleep quality, and vestibular symptoms persisted at one-year follow-up
A 2025 meta-analysis of seven randomized controlled trials and six prospective studies confirmed HBOT significantly improves general cognitive scores, memory, attention, executive function, and information processing speed in TBI patients

The largest TBI trial to date is now underway: USF Health's $28 million state-funded study is enrolling Florida service members and veterans in a five-year, randomized, double-blind, placebo-controlled design. This trial is expected to provide the definitive evidence needed to determine whether HBOT should become a standard treatment for military-related traumatic brain injury.

Sleep Quality Across Conditions

A 2026 retrospective study published in Frontiers in Neurology examined HBOT's effect on sleep quality across 395 patients in three clinical populations: healthy aging (n=180), long COVID (n=92), and PTSD (n=123). All participants underwent 60 HBOT sessions at 2.0 ATA with 100% oxygen, 90 minutes per session, five days per week.

The study found significant and robust improvements in patient-reported sleep quality across all three groups, with HBOT associated with improved sleep duration and reduced sleep latency. The researchers attributed the effect to HBOT's promotion of neuroplasticity through the hyperoxic-hypoxic paradox, which improves cerebral perfusion and reduces neuroinflammation.

Exercise-Induced Muscle Recovery

A 2026 systematic review and meta-analysis analyzed 10 studies comprising 299 subjects and found that HBOT significantly accelerated recovery from exercise-induced muscle injury. Key findings:

Both higher (>2.0 ATA) and lower (≤2.0 ATA) pressures were effective in alleviating muscle injury
Intervention durations of both 60 and 100 minutes showed benefits
However, HBOT did not enhance recovery from exercise-induced muscle soreness specifically
The distinction between structural muscle injury and delayed-onset soreness appears important for setting realistic expectations

Ulcerative Colitis

HBOT is emerging as a potential treatment for inflammatory bowel disease. A multi-center, randomized, double-blind, sham-controlled trial (HBOT-UC) published in 2025 is enrolling 126 participants with moderate to severe ulcerative colitis flares at UCLA and other centers. The trial randomizes participants to either HBOT plus standard IV steroids or sham hyperbaric air plus IV steroids, with clinical response at day 10 as the primary endpoint. See the inflammatory bowel disease evidence atlas for the full investigational evidence breakdown.

Two earlier small randomized controlled trials showed HBOT delivered to UC patients hospitalized for acute flares resulted in improved remission rates and avoidance of progression to biologics, small molecules, or colectomy. Case reports on outpatient HBOT for ulcerative colitis show response rates of 70% to 80%.

Anti-Aging and Longevity

A landmark study from Tel Aviv University and Shamir Medical Center found that 60 HBOT sessions over 90 days in healthy adults aged 64 and older produced remarkable results:

Telomere lengthening of up to 38% in immune cells
Reduction of senescent (aging) cells by up to 37%
A follow-up study published in Nature Scientific Reports (2024) confirmed these benefits persisted over one year after treatment ended

HBOT is increasingly viewed as a versatile platform for regeneration and healthy aging. A 2026 Frontiers research topic on "Oxygen as Medicine" is collecting studies focused specifically on HBOT's longevity applications, targeting hallmarks of aging including mitochondrial dysfunction, chronic inflammation, impaired stem cell niches, and genomic instability.

Metabolic Health

A 2024 review published in Antioxidants examined HBOT's potential for metabolic disorders. Preclinical studies have demonstrated that HBOT enhances insulin sensitivity, reduces adipose tissue inflammation, and modulates lipid metabolism, suggesting potential applications for metabolic syndrome and type 2 diabetes.

Autoimmune Conditions

A 2025 review in Frontiers in Medicine evaluated HBOT's clinical efficacy for rheumatic and immune diseases, concluding that HBOT significantly increases dissolved oxygen content in plasma and shows promising outcomes for reducing autoimmune inflammation. Conditions under investigation include reflex sympathetic dystrophy, Lyme disease, and multiple sclerosis, with studies currently underway to evaluate efficacy in controlled settings. See the multiple sclerosis evidence atlas for the full investigational evidence breakdown.

What the Research Does Not Yet Support

It is important to acknowledge the limitations of current evidence:

Cancer treatment: While some preclinical studies show potential, HBOT is not an established cancer therapy, and some concerns exist about oxygen promoting tumor growth in certain contexts
Autism spectrum disorder: Despite some anecdotal reports, randomized controlled trials have not shown consistent benefits
General wellness in healthy individuals: Most robust evidence applies to specific medical conditions, not general health optimization
Mild TBI in military populations: Four trials consistently found HBOT was no more effective than sham treatment for post-concussion symptoms in military personnel — though the ongoing USF Health $28 million trial may change this picture
Alzheimer's disease and macular degeneration: While studies are currently underway, these remain investigational with insufficient controlled data to draw conclusions

How Benefits Vary by Chamber Type

Not all HBOT is created equal. The type of chamber significantly affects the therapeutic potential:

Hard-shell chambers (medical-grade) deliver 100% oxygen at 2.0-3.0 ATA, achieving arterial oxygen levels of 1,824 mmHg
Soft-shell chambers (consumer-grade) typically reach only 1.3-1.4 ATA with 24% oxygen, achieving approximately 230 mmHg
Most published clinical research uses hard-shell chambers at pressures of 2.0 ATA or higher
The FDA has only cleared hard-shell chambers for medical treatment of the 14 approved conditions
The UHMS, AMA, and FDA have jointly warned that mild (soft-shell) HBOT devices marketed for home use do not deliver therapeutic pressures and may give patients a false sense of treatment

What a Typical Treatment Protocol Looks Like

Understanding the practical side of HBOT helps set realistic expectations:

Session length: 60-120 minutes per session, with 90 minutes being most common
Frequency: Daily sessions, typically 5 days per week
Total sessions: Most protocols call for 20-40 sessions depending on the condition (longevity and neurological protocols often use 60 sessions)
Cost range: $150-$600 per session, with hospital-based treatments on the higher end
Insurance coverage: Medicare, TRICARE, and most private insurers cover HBOT for FDA-approved conditions when deemed medically necessary

How to Evaluate HBOT for Your Situation

Before pursuing HBOT, consider these practical steps:

Check the evidence level: FDA-cleared conditions have the strongest support. Emerging applications may still be under investigation.
Consult your physician: HBOT is contraindicated for people with untreated pneumothorax, certain lung conditions, and some cardiac implants
Verify the facility: Look for UHMS (Undersea and Hyperbaric Medical Society) accredited centers with board-certified hyperbaric medicine physicians
Understand the commitment: Most conditions require 20-40 sessions, which means daily visits for several weeks
Ask about chamber type: Confirm whether the facility uses hard-shell, medical-grade chambers for your condition

Frequently Asked Questions

How quickly do people notice benefits from HBOT?

Most patients begin noticing improvements after 10-15 sessions, though some wound care patients report changes as early as session 5. The full course of 20-40 sessions is typically needed for maximum benefit. Anti-aging and neurological applications in research studies generally used 60 sessions over 90 days.

Is HBOT safe for older adults?

Yes, HBOT has been studied in adults aged 64 and older with a favorable safety profile. The Tel Aviv University longevity study specifically enrolled healthy older adults and reported no serious adverse events. Common mild side effects like ear pressure are manageable with proper equalization techniques.

Can HBOT replace other medical treatments?

HBOT is almost always used as an adjunctive (add-on) therapy, not a replacement for standard medical care. For wound healing, it supplements surgical debridement and wound care. For neurological conditions, it complements rehabilitation therapy. Always discuss HBOT with your primary care provider as part of a comprehensive treatment plan.

What is the difference between HBOT and breathing supplemental oxygen?

Regular supplemental oxygen (like a nasal cannula) delivers extra oxygen at normal atmospheric pressure. HBOT combines 100% oxygen with increased pressure, which allows oxygen to dissolve directly into blood plasma at much higher concentrations. This pressurized delivery reaches tissues that supplemental oxygen alone cannot adequately supply.

Are there any long-term risks of repeated HBOT sessions?

Long-term studies show HBOT is generally safe when administered within standard protocols. Temporary myopia (nearsightedness) can occur during a treatment course but typically resolves 6-8 weeks after stopping. A 2024 follow-up study of the anti-aging trial found no adverse effects over one year post-treatment. The risk of seizures or oxygen toxicity exists at high pressures but is very rare at the pressures used in routine clinical practice.

Does insurance cover HBOT for off-label conditions?

Generally, no. Medicare, TRICARE, and private insurers cover HBOT only for FDA-cleared indications when a physician certifies medical necessity. Off-label uses like long COVID, TBI, or anti-aging protocols are typically out-of-pocket expenses. Some facilities offer package pricing that reduces the per-session cost for multi-session protocols.

The Bottom Line

Hyperbaric oxygen therapy has a solid evidence base for its FDA-cleared indications, particularly wound healing, radiation injury, and decompression sickness. The pace of research into emerging applications has accelerated significantly through 2025 and 2026, with new clinical data on chronic venous leg ulcers, post-stroke depression, sleep quality, exercise recovery, ulcerative colitis, and long COVID strengthening the case for broader adoption.

Multiple large-scale trials are now underway. The USF Health $28 million TBI study, the multi-center HBOT-UC trial for ulcerative colitis, and the growing body of prospective registry data for long COVID represent the kind of rigorous, controlled research that will clarify which emerging applications cross the threshold from promising to proven.

For now, the strongest recommendation is to pursue HBOT for FDA-cleared conditions under the guidance of a qualified hyperbaric medicine physician, and to monitor the growing body of evidence for emerging applications.

Quick Answer